Clinical trial
Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who…
NCT00087958 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00087958 |
|---|---|
| Title | Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment |
| Official title | Phase II Multi-Center, Open-Label, Non-Randomized Study of Intravenous RPR109881 Given Every 3 Weeks in Patients With Metastatic Breast Cancer Progressing After Therapy With Anthracyclines, Taxanes and Capecitabine |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | XRP9881 |
| Enrollment | 168 |
| Start date | Aug 1, 2004 |
| Primary completion | Feb 1, 2007 |
| Completion | Apr 1, 2009 |
| First posted | Jul 20, 2004 |
| Last update posted | May 1, 2009 |
| Countries | Argentina, Belgium, Canada, Colombia, Denmark, France, Germany, Italy, Netherlands, South Africa, South Korea, Spain and 3 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: